sf3b1 as therapeutic target in flt3/itd positive aml
Published 3 years ago • 86 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
2:29
flt3 inhibitors as maintenance therapy in aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
7:16
lab 1 overview: tools of the trade
-
41:52
training/pelatihan/tutorial hematology analyzer sfri h18
-
7:08
ts&r series 3m tape head trouble shooting
-
1:32
novel treatment combinations for flt3-mutated aml
-
2:15
targeting flt3 in aml
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:56
the impact of sf3b1 mutations in myelofibrosis
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
1:26
combining flt3 and syk inhibition for aml
-
3:46
variant allele frequency in patients with sf3b1-mutated mds
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
2:10
the impact of sf3b1 mutation in myelofibrosis
-
0:58
flt3 mutation clearance rate in patients with newly diagnosed aml
-
2:54
quantum-first: association between flt3-itd-specific mrd clearance and survival in patients with aml
-
2:55
the importance of flt3 inhibitors in aml and factors to consider when choosing between these agents
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
3:03
quantum-first: flt3-itd-specific mrd to assess benefits of quizartinib in flt3-itd aml